NeuroDex has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to study, “Blood Test for Parkinson’s Stratification based on Neuron and Oligodendrocyte Derived Extracellular Vesicles.”
The award will enable NeuroDex to utilize its unique ExoSORT™ platform to measure α-Synuclein in blood plasma Neuron and Oligodendrocyte-derived exosomes. α-Synuclein is expressed by many cell types, however, in diseases like Parkinson’s disease, Lewy body dementia, and multiple system atrophy, the protein aggregates in the brain. Currently, there is no blood-based biomarker for α-Synuclein pathology, and this proposal aims to utilize Neuron and Oligodendrocyte-derived exosomes to develop the first such assay.
Dr. Erez Eitan, PhD., Co-Founder and Chief Scientific Officer of NeuroDex stated, “We’re excited to have the opportunity to leverage ExoSORT – our robust exosome immunoaffinity isolation procedure to develop a blood α-Synuclein assay that can potentially help in identification and stratification of different synucleinopathies.”
Mr. Oded Biran, the Company’s CEO stated, “We are proud to receive funding from The Michael J. Fox Foundation on this mission to develop blood-based biomarkers for synucleinopathies.” Mr. Biran added, “We believe that this grant funding, combined with the SBIR and CDMRP grants which were awarded to the Company late last year, validate our position as a leader in the cell specific exosome diagnostics field generally, and in the neurodegenerative space specifically.”
Source – EIN Newswire